About Us:

Foundation News


About Us: Foundation News

SMA Foundation and PTC Therapeutics Expand Partnership and Commit to an Initial Investment of Up to $60M to Advance Drug Discovery and Development Research in Regenerative Medicine

March 9, 2021

The Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics have entered a new collaboration focused on regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders. Recent FDA approvals of several disease modifying therapies for SMA has made regenerative medicine approaches the next frontier in drug discovery and development. The SMA Foundation-PTC…

Read More

The Spinal Muscular Atrophy Foundation Rings Nasdaq Opening Bell

August 18, 2018

The Spinal Muscular Atrophy (SMA) Foundation, a non-profit, organization whose mission is to accelerate the development of treatments for SMA, the leading cause of genetic death in young children, visited the Nasdaq MarketSite in Times Square on August 17, 2018. In honor of the occasion, Dinakar Singh, Co-Founder and Chairman of the Board of Directors,…

Read More

CombinatoRx Inks R&D Deal With Foundation

September 13, 2004

CombinatoRx Inc. of Boston has inked a multimillion-dollar, two-year research and development deal with a foundation to find treatments for spinal muscular atrophy, a neuromuscular disease. The Boston startup said its deal with the New York-based Spinal Muscular Atrophy Foundation calls for two years of research and development funding from the foundation. CombinatoRx will also…

Read More

Curis Lands $5.4M Spinal Muscular Atrophy Grant

September 7, 2004

Curis Inc., a Cambridge-based drug developer, received a $5.4 million three-year grant to help treat spinal muscular atrophy, the company announced Tuesday. The Spinal Muscular Atrophy Foundation awarded the grant to Curis to identify therapeutic compounds that could be used to treat the neuromuscular disease, which is the leading genetic cause of infant and toddler…

Read More

Curis Awarded $5.4M to Identify Treatment for Spinal Muscular Atrophy

September 7, 2004

Curis Inc. in Cambridge has received a $5.4 million, three-year grant from the Spinal Muscular Atrophy Foundation to identify therapeutic compounds to treat spinal muscular atrophy, a debilitating neuromuscular disease that is the leading genetic cause of infant and toddler death. The study will use proprietary Curis technologies and expertise to develop and refine motor…

Read More

The AAN Foundation and the SMA Foundation Announce the Recipients of the 2004 Young Investigator Award in SMA

April 19, 2004

New York, NY – April 19, 2004 – The Spinal Muscular Atrophy Foundation today announced that it has awarded new research grants totaling $1.125 million to four outstanding Young Investigators specializing in research on Spinal Muscular Atrophy (SMA), the leading genetic killer of infants and toddlers. These grants support the implementation and advancement of clinical research…

Read More

Assay Designs, Inc. and the Spinal Muscular Atrophy Foundation announce collaboration

January 1, 1970

ANN ARBOR, Mich. — Sept. 15, 2008 – Assay Designs and the Spinal Muscular Atrophy Foundation (SMAF) are very pleased to announce a collaborative agreement for development of reagents and assays for SMN (Survival Motor Neuron) protein to expedite drug discovery and development efforts for spinal muscular atrophy (SMA), the leading genetic cause of mortality in…

Read More